Licensing Custodian The IP and assets are licensed to 33 Medical since a liquidity event in 2022, making 33 Medical the primary commercialization partner. Pursue co development, expanded indications, or geography specific licensing with 33 Medical and potential new licensees to accelerate market access.

Clinically Validated The program has completed multiple pre clinical and human clinical studies demonstrating efficacy, providing a credible evidence base for hospitals, surgeons, and payers. Leverage this data to initiate conversations with spine centers and payer groups about reimbursement strategies and value based care initiatives.

Strategic Partnerships The spine device ecosystem features large incumbents seeking complementary minimally invasive solutions. Frame the technology as a low risk addition to existing portfolios and pursue strategic partnerships or potential acquisitions to scale distribution and adoption.

Ready to Partner With a lean team, execution is typically through partners and contract arrangements. Propose turnkey collaboration options such as joint development, distribution agreements, contract manufacturing, and regulatory support to speed commercialization.

Market Expansion The platform targets a high demand segment in discogenic lower back pain; explore expansion into related spine conditions or international markets using established distributor networks and regional sales teams to broaden reach.